Half-Year 2022 Financial and Clinical Trials Update

Actemra/RoActemra (tocilizumab, RG-1569) Interleukin 6 receptor inhibitor Indication Phase/study # of patients Design Primary endpoint Status " CT Identifier ☐ " ◉ ◉ Adult hospitalised with severe COVID-19 pneumonia Phase II MARIPOSA N=100 ARM A: 8 mg/kg Actemra plus standard of care ARM B: 4mg/kg Actemra plus standard of care Phase III EMPACTA N=379 Conducted in sites known to provide critical care to underserved and minority populations that often do not have access to clinical trials ARM A: Actemra plus standard of care ARM B: Placebo plus standard of care Pharmacodynamics and pharmacokinetics FPI Q2 2020 Recruitment completed Q2 2020 Published in Open Forum Infect Dis 2021 Dec 4;9(1) NEJM-New England Journal of Medicine NCT04363736 Roche Cumulative proportion of participants requiring mechanical ventilation by day 28 ■ FPI Q2 2020 Primary endpoint met Q3 2020 Published in NEJM 2021 Jan 7;384(1):20-30 Filed in EU Q3 2021 ☐ ▪ Approved in EU Q4 2021 NCT04372186 116 Immunology

View entire presentation